Evidence map›Paper›PMID 28835248›Full record

ArticleWorld journal of surgical oncology2017

Long-term survival following hepatectomy, radiation, and chemotherapy for recurrent pancreatic carcinoma: a case report.

Shigeru Fujisaki, Motoi Takashina, Ryouichi Tomita, Kenichi Sakurai, Tadatoshi Takayama

Open access · goldAbstract readCase Reports
In one paragraph

Article in World journal of surgical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Shigeru FujisakiDepartment of Surgery, Fujisaki Hospital, 1-25-11, Minamisuna, Kotoh-ku, Tokyo, 136-0076, Japan. sfujisak@blue.ocn.ne.jp.
Motoi TakashinaDepartment of Surgery, Fujisaki Hospital, 1-25-11, Minamisuna, Kotoh-ku, Tokyo, 136-0076, Japan.
Ryouichi TomitaDepartment of Surgery, Nippon Dental University School of life Dentistry, 2-3-16 Fujimi, Chiyoda-ku, Tokyo, 102-8158, Japan.
Kenichi SakuraiDivisions of Breast and Endocrine Surgery, Nihon University School of Medicine, 30-1, Oyaguchikamimachi, Itabashi-ku, Tokyo, 173-8610, Japan.
Tadatoshi TakayamaDigestive Surgery, Nihon University School of Medicine, 30-1, Oyaguchikamimachi, Itabashi-ku, Tokyo, 173-8610, Japan.
Fujisawa City Hospital · JPNihon University · JPNippon Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecurrent pancreatic carcinoma (PC) is generally well known to have a poor prognosis. Cases in which multidisciplinary treatments have been remarkably effective are rare. CASE PRESENTATION: Herein, we reported a case of long-term survival following a combination of hepatectomy for a liver metastasis and radiation and chemotherapy for abdominal lymph node metastases after a curative pancreaticoduodenectomy for PC. A 51-year-old Japanese man underwent a pancreaticoduodenectomy following a PC diagnosis in December 2011. After the surgery, the patient received 16 cycles of gemcitabine (GEM) adjuvant chemotherapy. Abdominal computed tomography (CT) after therapy with GEM (17 months after surgery) revealed a 1-cm nodule in the liver, for which the patient underwent partial hepatectomy in May 2013. Approximately 1 month after the hepatectomy, the patient underwent adjuvant chemotherapy using tegafur/gimeracil/oteracil (S-1) for 12 months. Approximately 1 year after the second surgery, an abdominal CT scan detected the abdominal lymph node metastases, for which the patient underwent radiation therapy. After the radiation therapy, combination therapy with 5-fluorouracil(5-FU)/leucovorin plus oxaliplatin or irinotecan was started in September 2014; 59 cycles of this chemotherapy have been administered up to the time of this report. At 67 months after the pancreaticoduodenectomy and 50 months after the hepatectomy, the patient has remained healthy with no relapse or recurrent lesions.

conclusionWe have managed a long-term survivor who underwent hepatectomy for liver metastasis and radiation therapy and chemotherapy for abdominal lymph node metastases after curative pancreaticoduodenectomy for PC.

Indexed as

Antimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsCancer SurvivorsChemotherapy, AdjuvantHepatectomyHumansLiver NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm Recurrence, LocalPancreatic NeoplasmsPancreaticoduodenectomyPrognosisRadiotherapy, AdjuvantTime FactorsAntimetabolites, AntineoplasticChemotherapyHepatectomyRadiationRecurrent pancreatic carcinoma

Identifiers

PMID28835248
PMCPMC5569547
OpenAlexW2747380442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.